eDreams ODIGEO S.A.

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, BYDGF has a market cap of 3.5B. Regarding current trading prices, EDEMY is priced at $40.00, while BYDGF trades at $161.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas BYDGF's P/E ratio is 423.92. In terms of profitability, EDEMY's ROE is +0.32%, compared to BYDGF's ROE of +0.02%. Regarding short-term risk, EDEMY is less volatile compared to BYDGF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check BYDGF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, CVSGF has a market cap of 1.2B. Regarding current trading prices, EDEMY is priced at $40.00, while CVSGF trades at $16.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas CVSGF's P/E ratio is 53.23. In terms of profitability, EDEMY's ROE is +0.32%, compared to CVSGF's ROE of +0.08%. Regarding short-term risk, EDEMY is more volatile compared to CVSGF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check CVSGF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, PRRWF has a market cap of 655.4M. Regarding current trading prices, EDEMY is priced at $40.00, while PRRWF trades at $19.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas PRRWF's P/E ratio is -91.33. In terms of profitability, EDEMY's ROE is +0.32%, compared to PRRWF's ROE of -0.01%. Regarding short-term risk, EDEMY is more volatile compared to PRRWF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check PRRWF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, CRLKP has a market cap of 498.7M. Regarding current trading prices, EDEMY is priced at $40.00, while CRLKP trades at $22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas CRLKP's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to CRLKP's ROE of +0.43%. Regarding short-term risk, EDEMY is more volatile compared to CRLKP. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check CRLKP's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, MIBE has a market cap of 80.3M. Regarding current trading prices, EDEMY is priced at $40.00, while MIBE trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas MIBE's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to MIBE's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to MIBE. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check MIBE's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, WOSSF has a market cap of 74.9M. Regarding current trading prices, EDEMY is priced at $40.00, while WOSSF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas WOSSF's P/E ratio is 5.50. In terms of profitability, EDEMY's ROE is +0.32%, compared to WOSSF's ROE of +0.23%. Regarding short-term risk, EDEMY is less volatile compared to WOSSF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check WOSSF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, MNNGF has a market cap of 58M. Regarding current trading prices, EDEMY is priced at $40.00, while MNNGF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas MNNGF's P/E ratio is -7.50. In terms of profitability, EDEMY's ROE is +0.32%, compared to MNNGF's ROE of +0.06%. Regarding short-term risk, EDEMY is less volatile compared to MNNGF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check MNNGF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, MNLXF has a market cap of 40.2M. Regarding current trading prices, EDEMY is priced at $40.00, while MNLXF trades at $0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas MNLXF's P/E ratio is -4.00. In terms of profitability, EDEMY's ROE is +0.32%, compared to MNLXF's ROE of +2.48%. Regarding short-term risk, EDEMY is less volatile compared to MNLXF. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check MNLXF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, KVIL has a market cap of 30.5M. Regarding current trading prices, EDEMY is priced at $40.00, while KVIL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas KVIL's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to KVIL's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to KVIL. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check KVIL's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, GDDFF has a market cap of 18.1M. Regarding current trading prices, EDEMY is priced at $40.00, while GDDFF trades at $0.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas GDDFF's P/E ratio is -1.82. In terms of profitability, EDEMY's ROE is +0.32%, compared to GDDFF's ROE of +0.46%. Regarding short-term risk, EDEMY is more volatile compared to GDDFF. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check GDDFF's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, AMIH has a market cap of 195K. Regarding current trading prices, EDEMY is priced at $40.00, while AMIH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas AMIH's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to AMIH's ROE of +0.64%. Regarding short-term risk, EDEMY is less volatile compared to AMIH. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check AMIH's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, GDET has a market cap of 89.9K. Regarding current trading prices, EDEMY is priced at $40.00, while GDET trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas GDET's P/E ratio is -0.10. In terms of profitability, EDEMY's ROE is +0.32%, compared to GDET's ROE of +0.05%. Regarding short-term risk, EDEMY is more volatile compared to GDET. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check GDET's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, BZRT has a market cap of 53.5K. Regarding current trading prices, EDEMY is priced at $40.00, while BZRT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas BZRT's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to BZRT's ROE of +0.00%. Regarding short-term risk, EDEMY is more volatile compared to BZRT. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check BZRT's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, AIOM has a market cap of 34K. Regarding current trading prices, EDEMY is priced at $40.00, while AIOM trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas AIOM's P/E ratio is -0.03. In terms of profitability, EDEMY's ROE is +0.32%, compared to AIOM's ROE of -0.10%. Regarding short-term risk, EDEMY is less volatile compared to AIOM. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check AIOM's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, PTTL has a market cap of 7.1K. Regarding current trading prices, EDEMY is priced at $40.00, while PTTL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas PTTL's P/E ratio is -0.01. In terms of profitability, EDEMY's ROE is +0.32%, compared to PTTL's ROE of -1.53%. Regarding short-term risk, EDEMY is more volatile compared to PTTL. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check PTTL's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, PNGB has a market cap of 4.9K. Regarding current trading prices, EDEMY is priced at $40.00, while PNGB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas PNGB's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to PNGB's ROE of +15.99%. Regarding short-term risk, EDEMY is less volatile compared to PNGB. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check PNGB's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, CVSC has a market cap of 1.7K. Regarding current trading prices, EDEMY is priced at $40.00, while CVSC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas CVSC's P/E ratio is 0.01. In terms of profitability, EDEMY's ROE is +0.32%, compared to CVSC's ROE of N/A. Regarding short-term risk, EDEMY is less volatile compared to CVSC. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check CVSC's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, OBDP has a market cap of 163. Regarding current trading prices, EDEMY is priced at $40.00, while OBDP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas OBDP's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to OBDP's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to OBDP. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check OBDP's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, PXRB has a market cap of 82. Regarding current trading prices, EDEMY is priced at $40.00, while PXRB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas PXRB's P/E ratio is -0.00. In terms of profitability, EDEMY's ROE is +0.32%, compared to PXRB's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to PXRB. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check PXRB's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, VLBI has a market cap of 11. Regarding current trading prices, EDEMY is priced at $40.00, while VLBI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas VLBI's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to VLBI's ROE of -0.54%. Regarding short-term risk, EDEMY is more volatile compared to VLBI. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check VLBI's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, CPLT has a market cap of 2. Regarding current trading prices, EDEMY is priced at $40.00, while CPLT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas CPLT's P/E ratio is 0.00. In terms of profitability, EDEMY's ROE is +0.32%, compared to CPLT's ROE of N/A. Regarding short-term risk, EDEMY is more volatile compared to CPLT. This indicates potentially higher risk in terms of short-term price fluctuations for EDEMY.Check CPLT's competition here

EDEMY plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EDEMY stands at 421.5M. In comparison, SPRJ has a market cap of 0. Regarding current trading prices, EDEMY is priced at $40.00, while SPRJ trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EDEMY currently has a P/E ratio of 5.12, whereas SPRJ's P/E ratio is N/A. In terms of profitability, EDEMY's ROE is +0.32%, compared to SPRJ's ROE of N/A. Regarding short-term risk, EDEMY is less volatile compared to SPRJ. This indicates potentially lower risk in terms of short-term price fluctuations for EDEMY.Check SPRJ's competition here